Import from '@/components/mdx'

AOD-9604 Biohacker and Longevity Stack Protocol for Women: What the Evidence Actually Says

What Is AOD-9604 and Why Is It in Longevity Stacks?

AOD-9604 is a 16-amino-acid synthetic peptide representing the C-terminal end of human growth hormone. Researchers at Monash University first synthesized it in the 1990s with the aim of separating hGH's fat-metabolizing effects from its insulin-resistance and growth-promoting effects.

The longevity-influencer community picked it up because it theoretically targets lipolysis, specifically stimulating beta-3 adrenergic receptors in adipose tissue and inhibiting lipogenesis, without raising IGF-1 in the way full hGH does. That distinction matters to women: elevated IGF-1 over long periods has been associated with modest increases in breast cancer risk in observational data, though direct causation from short-cycle AOD-9604 use has not been studied.

The Evidence Field (and Its Honest Gaps)

The strongest human data comes from the METAOD clinical trial series conducted by Metabolic Pharmaceuticals in Australia. The Phase II trials enrolled overweight and obese adults and tested oral AOD-9604 at doses from 1 mg to 54 mg daily. In the published 12-week Phase II RCT, a 1 mg oral dose produced statistically significant fat mass reduction compared with placebo, without raising fasting glucose or IGF-1.

There are three critical caveats every woman in a longevity stack should understand:

1. Those trials used oral administration; almost all current influencer protocols use subcutaneous injection, a different route with different bioavailability that has not been tested in peer-reviewed human trials.
2. The Phase III program failed to demonstrate adequate efficacy for FDA approval, and development was halted.
3. Women were enrolled in the METAOD trials but were not analyzed as a sex-stratified subgroup, so women-specific dose-response data does not exist in the literature.

This is not a minor gap. Women have measurably different growth hormone secretion patterns. Estrogen amplifies GH pulse amplitude; progesterone blunts it. A perimenopausal woman with declining estrogen will have a meaningfully different GH axis than a 35-year-old in the follicular phase, and neither of those profiles was studied separately in the METAOD data.

The Subcutaneous Route: What We Know and What We Are Extrapolating

Current longevity-community protocols assume subcutaneous AOD-9604 is active at roughly 200 to 500 mcg per day. This is extrapolated from the oral data using assumed gut-wall losses, not from a published pharmacokinetic study in humans. The FDA's database lists no approved application for subcutaneous AOD-9604, and no compounding pharmacy study has been peer reviewed. Women using subcutaneous protocols are working from practitioner experience and community reports, not from a human RCT of this specific route.

A Structured Protocol for Women Considering AOD-9604

This protocol reflects the dose and timing conventions most commonly used in longevity-oriented clinical practices. Evidence level is labeled per claim.

Dose and Route

The most frequently cited starting dose in practitioner-guided contexts is 250 mcg subcutaneous injection daily, injected into abdominal subcutaneous fat. Some protocols escalate to 300 mcg after four weeks if no adverse effects appear. Doses above 500 mcg are not supported by any human clinical data and are not recommended here.

Women with a BMI <27 who are stacking AOD-9604 for general longevity rather than active fat loss should consider whether the risk-benefit calculation is favorable at all, given that the primary trial populations were overweight or obese.

Timing and Fasting State

The oral METAOD data administered the peptide in a fasted state. Subcutaneous influencer protocols mirror this by recommending morning injection 30 to 60 minutes before food or 2 to 3 hours after the last meal. The rationale is that elevated insulin from feeding may blunt lipolytic signaling. This rationale is mechanistically plausible but not confirmed for the subcutaneous route in a human trial. Evidence level: extrapolated from oral RCT plus basic GH-axis physiology (observational grade).

Cycle Length

Most longevity-practice protocols run 12 to 16 weeks, then take an 8-week break. This mirrors the METAOD oral trial duration. No published data addresses what happens with continuous use beyond 16 weeks in humans. The concern is not IGF-1 elevation (the peptide appears not to raise it significantly), but rather receptor desensitization at adipose beta-3 sites. Evidence level: anecdotal practitioner experience.

Combination Stacking: What Women Add and What to Consider

Longevity influencers often stack AOD-9604 with one or more of the following:

• CJC-1295 / Ipamorelin: GHRH analogue and GHRP, aimed at increasing endogenous GH pulse amplitude. In women, this combination may amplify estrogen-driven GH pulses in the follicular and pre-ovulatory phases, potentially increasing fat-loss effect but also increasing the risk of fluid retention and carpal tunnel symptoms, which are more common in women on GH-related compounds.
• BPC-157: Used for tissue repair and gut health. No known pharmacokinetic interaction with AOD-9604; evidence for this combination is anecdotal only.
• Semaglutide or tirzepatide: Some practitioners layer AOD-9604 with a GLP-1 receptor agonist. There are no interaction data. GLP-1 agonists have demonstrated 15 to 22% body weight reduction in RCTs with strong safety data, making them the evidence-supported first-line pharmacologic option for weight management in women. AOD-9604 has a far thinner evidence base by comparison.
• Thyroid optimization (T3/T4): Several longevity protocols add thyroid support, particularly in perimenopausal women with subclinical hypothyroidism. This is a separate clinical question; thyroid status should be optimized first because hypothyroidism itself suppresses GH pulsatility and would blunt any AOD-9604 effect.

WomanRx Life-Stage Stacking Framework for AOD-9604:

| Life Stage | Relevant Hormonal Variable | Practical Implication | |---|---|---| | Reproductive years (regular cycles) | Estrogen amplifies GH pulses; effect varies by cycle phase | Consider timing injection in follicular phase when GH axis is most active | | Trying to conceive | Unknown embryo safety | Discontinue at least 3 months before attempting conception | | Perimenopause | Declining estrogen blunts GH amplitude | May need dose at lower end; monitor for worsening insulin sensitivity | | Post-menopause (no HRT) | Low estrogen, blunted GH | Theoretical benefit reduced; metabolic labs more important to monitor | | Post-menopause (on estrogen HRT) | Oral estrogen raises GH binding protein and may alter distribution | Subcutaneous or transdermal estrogen users may have different GH dynamics than oral HRT users |

Monitoring Labs and Expected Timeline

Every woman using AOD-9604 in a longevity stack should have baseline and follow-up labs. This is not negotiable and is what separates a clinical protocol from self-experimentation.

Baseline Labs (Before Starting)

• Fasting glucose and fasting insulin (calculate HOMA-IR)
• HbA1c
• Full lipid panel
• IGF-1
• Thyroid panel (TSH, free T4, free T3)
• Comprehensive metabolic panel
• DEXA body composition scan for fat mass and lean mass tracking
• In perimenopausal and post-menopausal women: FSH, estradiol, and if on HRT, review current therapy before adding any GH-axis peptide

Follow-Up Labs (Week 8 and Week 16)

• Repeat fasting glucose, insulin, HbA1c
• Repeat IGF-1 (expect no significant rise; if IGF-1 rises above the upper quartile for age, discontinue)
• Repeat lipid panel
• Repeat DEXA at 16 weeks for objective body composition data

Expected Timeline of Outcomes (Evidence-Graded)

• Weeks 1 to 4: Minimal subjective change. Some women report reduced appetite (mechanism unclear; not confirmed in trials). Evidence level: anecdotal.
• Weeks 4 to 8: Modest fat mass reduction in individuals with higher baseline adiposity. The METAOD Phase II data showed approximately 1.4 kg more fat loss than placebo over 12 weeks with oral dosing, which is modest. Extrapolating to subcutaneous at 250 mcg is speculative.
• Weeks 8 to 16: Where most practitioners report peak effect. DEXA is the only reliable way to confirm whether any change is fat mass vs fluid or lean mass.
• Post-cycle: No published washout or rebound data in humans. Maintain dietary and exercise habits established during the cycle.

Pregnancy, Lactation, and Contraception: A Non-Negotiable Section

AOD-9604 is contraindicated in pregnancy. There are no human pregnancy safety data. Animal studies used in the original development program are not fully published in the peer-reviewed literature. Because AOD-9604 acts on adipokine pathways and potentially on placental growth-factor signaling, the theoretical risk to a developing embryo or fetus cannot be dismissed.

If you are pregnant or think you may be pregnant, do not start or continue AOD-9604. This is a firm stop.

Trying to conceive: Discontinue AOD-9604 at least three months before attempting conception. This conservative washout window mirrors guidance used for other investigational peptides, given that no human pharmacokinetic elimination data have been published for the subcutaneous form.

Lactation: No lactation transfer data exist for AOD-9604. The American Academy of Pediatrics' framework for drugs with no lactation data recommends avoidance. Do not use AOD-9604 while breastfeeding.

Contraception requirement: Any woman of reproductive age using AOD-9604 should use reliable contraception during the cycle. Hormonal contraception does not interact with AOD-9604 in any published study, but note that combined oral contraceptives raise GH binding protein levels, which could theoretically alter GH-axis dynamics during a peptide stack. Transdermal or non-hormonal contraception avoids this theoretical variable.

PCOS: Women with polycystic ovary syndrome frequently have altered GH pulsatility, higher baseline IGF-1, and insulin resistance. AOD-9604's proposed mechanism of improving insulin sensitivity is theoretically appealing, but no trial has enrolled a PCOS-specific cohort. Women with PCOS should have tighter glucose monitoring (every four weeks rather than every eight) during any trial of this peptide.

Who This Protocol May Be Right For and Who Should Avoid It

May Be Appropriate For

• Women in their 30s to 50s with documented excess adiposity who have optimized diet, exercise, and sleep, and who have had a thorough clinical evaluation
• Perimenopausal women on stable hormone therapy who want an adjunctive body-composition intervention and whose clinician is monitoring labs
• Women who cannot tolerate or do not qualify for GLP-1 agonists and are seeking an alternative with physician oversight

Should Not Use AOD-9604

• Pregnant women or anyone planning pregnancy in the next 3 months
• Breastfeeding women
• Women with active or personal history of hormone-receptor-positive breast cancer (GH-axis stimulation in this context has not been studied and introduces theoretical risk)
• Women with poorly controlled type 2 diabetes or insulin-dependent diabetes (the METAOD trials excluded patients with significant glycemic disease)
• Women with active hyperthyroidism or untreated hypothyroidism (thyroid status confounds GH axis interpretation)
• Women under 18 or over 70 (no data in these age groups)

The Honest Evidence Grade Summary

Being direct about evidence quality is a clinical obligation, not a disclaimer.

| Claim | Evidence Level | |---|---| | AOD-9604 reduces fat mass compared with placebo | Phase II RCT (oral, 12 weeks, METAOD program) | | Subcutaneous route at 250 to 300 mcg is effective | Practitioner extrapolation; no peer-reviewed human RCT | | AOD-9604 does not raise IGF-1 significantly | Phase II RCT data (oral); subcutaneous route unconfirmed | | No significant effect on fasting glucose | Phase II RCT data (oral) | | Women-specific dose-response data | Does not exist in published literature | | Combination stacking benefit | Anecdotal; no human trial data | | Pregnancy/lactation safety | No data; contraindicated by absence of safety evidence |

Women have been consistently underrepresented in peptide research. The METAOD program enrolled mixed-sex cohorts and reported aggregate results. Regulatory filings for AOD-9604 as an obesity drug were withdrawn before sex-stratified data were published. If you are a woman using this peptide, you are operating substantially on extrapolation. That is the honest reality, and a clinician who tells you otherwise is overstating the data.

AOD-9604 vs. The Evidence-Supported Alternatives

Before committing to a protocol with thin human data, every woman should know what the comparison looks like.

Semaglutide (Wegovy) produced mean body weight loss of 14.9% at 68 weeks in the STEP 1 trial, which enrolled 2,000+ participants and had sex-stratified reporting. Tirzepatide (Zepbound) produced up to 22.5% weight loss at 72 weeks in the SURMOUNT-1 trial with a large female cohort. These are not comparisons designed to discourage peptide exploration, they are the clinical context a woman deserves before layering a compounded investigational compound into her stack.

AOD-9604 may have a role as an adjunct in women who are already at a healthy weight and are targeting body-composition refinement rather than clinically significant weight loss. That use case has even less direct evidence, but it is also a lower-stakes application in terms of metabolic risk.

Sourcing, Compounding, and Quality Control

AOD-9604 is not FDA-approved. In the US, it is available from compounding pharmacies that operate under FDA oversight for personalized prescriptions, or from research chemical suppliers who sell it as "not for human use." These are meaningfully different categories.

If you are using AOD-9604 clinically, it should come from a licensed 503A or 503B compounding pharmacy that provides a certificate of analysis (CoA) for every batch. Research chemical suppliers are not subject to pharmaceutical manufacturing standards and have documented issues with dosing accuracy and sterility in independent testing. The FDA has issued warnings about compounded peptides that lack adequate quality controls. Request the CoA. Review it with your prescriber.

Your prescribing clinician should be licensed, should document your indication and labs, and should not be prescribing AOD-9604 without a clinical context for your individual case.